0001209191-18-047874.txt : 20180821 0001209191-18-047874.hdr.sgml : 20180821 20180821200234 ACCESSION NUMBER: 0001209191-18-047874 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180817 FILED AS OF DATE: 20180821 DATE AS OF CHANGE: 20180821 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bujarski Robert Joseph CENTRAL INDEX KEY: 0001333458 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-10961 FILM NUMBER: 181031254 MAIL ADDRESS: STREET 1: C/O QUIDEL CORPORATION STREET 2: 12544 HIGH BLUFF DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: QUIDEL CORP /DE/ CENTRAL INDEX KEY: 0000353569 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 942573850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12544 HIGH BLUFF DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 8585521100 MAIL ADDRESS: STREET 1: 12544 HIGH BLUFF DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: MONOCLONAL ANTIBODIES INC /DE/ DATE OF NAME CHANGE: 19910210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-08-17 0 0000353569 QUIDEL CORP /DE/ QDEL 0001333458 Bujarski Robert Joseph 12544 HIGH BLUFF DRIVE, SUITE 200 SAN DIEGO CA 92130 0 1 0 0 SVP, Bus Dev & Gen Counsel Common Stock 2018-08-17 4 M 0 7156 27.57 A 53537 D Common Stock 2018-08-17 4 M 0 8798 23.41 A 62335 D Common Stock 2018-08-17 4 M 0 17596 15.40 A 79931 D Common Stock 2018-08-17 4 S 0 38550 70.1491 D 41381 D Non-qualified Stock Options 27.57 2018-08-17 4 M 0 7156 0.00 D 2024-02-24 Common Stock 7156 0 D Non-Qualified Stock Options 23.41 2018-08-17 4 M 0 8798 0.00 D 2025-02-05 Common Stock 8798 8798 D Non-Qualified Stock Options 15.40 2018-08-17 4 M 0 17596 0.00 D 2026-02-10 Common Stock 17596 17596 D The weighted average sale price for these transactions was $70.1491 per share, with a range of $69.755 to $70.71. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares sold at each separate price. 14,130 shares vested on 2/24/2016; 7,155 shares vested on 2/24/2017; 7,156 shares vested on 2/24/2018. 17,596 shares vested on 2/5/2017; 8,798 shares vested on 2/5/2018; 8,798 shares will vest on 2/4/2019. 17,596 shares vested on 2/10/2018; 8,798 shares will vest on 2/10/2019; 8,798 shares will vest on 2/10/2020. All transactions reported herein were effected pursuant to a pre-established 10b5-1 trading plan. Robert J. Bujarski 2018-08-21